- British International Investment targets £9 billion of new capital for Africa
- A New Rates Regime: Managing Volatility Post-War - Shane O'Neill, Global Head of Capital Markets
- Break The Mold: Reshaping The Future of African Private Capital
- US Government Equity and Equity-Linked Investments in Critical Minerals - Mayer Brown
- BRVM INVESTMENT DAYS 2026 COMES TO NEW YORK: Positioning WAEMU as an Emerging Destination for Global Investors
South Africa Wary of Sputnik, CanSino Shots Because of HIV Risk
JOHANNESBURG (Capital Markets in Africa) — Russia’s Sputnik V vaccine, CanSino Biologics Inc.’s shot, and other Covid-19 immunizations relying on a cold virus that’s backfired in the past should show they don’t make people more vulnerable to HIV infection before gaining approval in South Africa, the head of a local vaccine company said. Sputnik V, CanSino’s injection, and another vaccine in development from ImmunitiBio Inc. use a harmless cold germ called adenovirus type-5 to carry…
Read More







